Greater Glasgow and Clyde Medicines

Latest Medicines Updates & News

Yellow Card Reporting

Posted: Tuesday, June 16, 2026

Category - Medicines Update

Click here to access the full blog

  • As little as one adverse drug reaction (ADR) report can generate a safety signal, so every report counts.
  • All healthcare professionals involved in patient care have a responsibility to report suspected ADRs.
  • Reporting ADRs to the Yellow Card Scheme is quick and easy and can be done via the Yellow Card website or through the Yellow Card app (available on the App Store or Google Play). The MHRA has implemented Multi-Factor Authentication (MFA) to the Yellow Card website and app to enhance security to protect personal data.
  • When reporting, provide as much information as possible. Only four pieces of information are required to submit a report: medicine name, suspected reaction (with as much detail as possible), at least one patient identifier and reporter details.
  • Anyone can report an issue with medicines (including herbal or homeopathic), vaccines or nicotine containing e-cigarette and/or e-liquid to the Yellow Card Scheme. Healthcare professionals in Scotland should report issues related to medical devices (including blood glucose monitors, apps or insulin pumps) to the Incident Reporting & Investigation Centre (IRIC) and blood products to the Scottish National Blood Transfusion Service.
  • ALL suspected ADRs to new medicines and vaccines under additional monitoring (black triangle scheme) should be reported regardless of severity and if they are already included in the Summary of Product Characteristics (SmPC). Information on black triangle medicines can be found in the BNF, BNFC or SmPC.
Read More...

Formulary Update June 2026

Posted: Thursday, June 11, 2026

Category - Formulary Update

This post summarises the latest NHS Greater Glasgow and Clyde decisions relating to new medicines assessed by SMC and considered by the Area Drug and Therapeutics Committee (ADTC) and uses a nationally developed format specifically aimed for patients and the public.

For full details of the medicines included in this post that are available for use, including any restrictions on prescribing, please see the relevant entry in the GGC Formulary.

Read More...

GGC Guideline Update: Heparin dose adjustment in the presence of renal impairment

Posted: Tuesday, May 5, 2026

Category - Medicines Update

Click here to access the full blog

  • The NHSGGC Heparin Dose Adjustment in the Presence of Renal Impairment guideline has been updated.
  • The updated NHSGGC guideline includes:
    • Updated advice for thromboprophylaxis and monitoring requirements in patients with creatinine clearance (CrCl) <15mL/min.
    • Updated advice for therapeutic heparin dosing for patients with CrCl <15mL/min.
    • Updated guidance for anticoagulation during haemodialysis.
Read More...

Formulary Update April 2026

Posted: Tuesday, April 28, 2026

Category - Formulary Update

This post summarises the latest NHS Greater Glasgow and Clyde decisions relating to new medicines assessed by SMC and considered by the Area Drug and Therapeutics Committee (ADTC) and uses a nationally developed format specifically aimed for patients and the public.

For full details of the medicines included in this post that are available for use, including any restrictions on prescribing, please see the relevant entry in the GGC Formulary.

Read More...

Managing adult patients’ Hepatitis C medicines in NHSGGC acute care

Posted: Monday, April 27, 2026

Category - Medicines Update

Click here to access the full blog

  • Most patients with Hepatitis C Virus (HCV) will be treated with oral direct-acting antiviral agents (DAAs) for 8-12 weeks.
  • DAAs should be continued during the hospital stay, unless the clinical condition of the patient precludes administration.
  • Check for drug interactions with any new medicines; a useful source is www.hep-druginteractions.org.
  • The HCV pharmacy team (see contact details in blog) can confirm the patient’s current regimen and provide clinical advice on safe/effective use of DAAs.
  • Where available, use the patient’s own drugs (PODs). See ‘Administration and supply’ section for the process to follow if PODs are not available.
  • At discharge, if the DAA regimen is dispensed in the community, contact the patient’s community pharmacy to ask them to resume supply.
Read More...